Central African Republic vs Papua New Guinea: Immunization, Hib3
Central African Republic
42.0%
in 2024
Papua New Guinea
42.0%
in 2024
Central African Republic rank
188th
Papua New Guinea rank
188th
Immunization, Hib3 over time
- Central African Republic
- Papua New Guinea
How they compare
Central African Republic currently reports 42.0% against 42.0% in Papua New Guinea, a difference of 0.0%.
The two have swapped places 6 times across 16 shared years of data; in 2009 it was Papua New Guinea ahead.
Central African Republic ranks 188th and Papua New Guinea ranks 188th of 191 countries.
Across the 3 decades both report, Central African Republic averaged higher in 1 and Papua New Guinea in 2.
Head to head by decade
| Decade | Central African Republic | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 42.0% | 64.0% | 22.0% | Papua New Guinea |
| 2010s | 41.2% | 48.2% | 7.0% | Papua New Guinea |
| 2020s | 37.4% | 37.2% | 0.2% | Central African Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Central African Republic or Papua New Guinea?
- Central African Republic, at 42.0% against 42.0% in Papua New Guinea as of 2024.
- What is the difference in immunization, hib3 between Central African Republic and Papua New Guinea?
- 0.0%, with Central African Republic ahead.
- How many years of comparable data are there for Central African Republic and Papua New Guinea?
- 16 years are reported by both, from 2009 to 2024.
- How do Central African Republic and Papua New Guinea rank globally for immunization, hib3?
- Central African Republic ranks 188th and Papua New Guinea ranks 188th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.